S A Harrison

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. ncbi request reprint Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Stephen A Harrison
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    Hepatology 52:864-74. 2010
  2. ncbi request reprint New treatments for nonalcoholic fatty liver disease
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Gastroenterol Rep 8:21-9. 2006
  3. pmc Benefits of lifestyle modification in NAFLD
    Stephen A Harrison
    Gastroenterology and Hepatology Division, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    Gut 56:1760-9. 2007
  4. doi request reprint Abnormal liver tests and fatty liver on ultrasound
    Stephen A Harrison
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Clin Gastroenterol Hepatol 6:26-9. 2008
  5. ncbi request reprint Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, Texas 78324, USA
    Clin Gastroenterol Hepatol 6:864-76. 2008
  6. doi request reprint Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
    Stephen A Harrison
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 49:80-6. 2009
  7. doi request reprint Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
    S A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, USA
    Gut 57:1441-7. 2008
  8. ncbi request reprint Current treatments in nonalcoholic steatohepatitis
    Dawn M Torres
    Stephen A Harrison, MD Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Treat Options Gastroenterol 10:425-34. 2007
  9. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
  10. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy
    Stephen A Harrison
    Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
    Hepatology 52:864-74. 2010
    ..6, 95% confidence interval (CI) = 1.4-1.8, P < 0.001], a low HDL level (OR = 0.5, 95% CI = 0.3-0.8, P = 0.004), and statin use (OR = 2.0, 95% CI = 1.1-3.7, P = 0.02) were independently associated with SVR...
  2. ncbi request reprint New treatments for nonalcoholic fatty liver disease
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Gastroenterol Rep 8:21-9. 2006
    ..Future treatment for patients failing to achieve weight loss goals is likely to consist of combination therapy targeting insulin resistance, oxidative stress, and fibrogenesis...
  3. pmc Benefits of lifestyle modification in NAFLD
    Stephen A Harrison
    Gastroenterology and Hepatology Division, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    Gut 56:1760-9. 2007
  4. doi request reprint Abnormal liver tests and fatty liver on ultrasound
    Stephen A Harrison
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Clin Gastroenterol Hepatol 6:26-9. 2008
  5. ncbi request reprint Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, Texas 78324, USA
    Clin Gastroenterol Hepatol 6:864-76. 2008
    ..Studies are under way to determine whether improving insulin sensitivity results in better outcomes in patients receiving pegylated interferon alfa plus ribavirin therapy for chronic hepatitis C...
  6. doi request reprint Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
    Stephen A Harrison
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 49:80-6. 2009
    ..However, subjects who lost >or=5% of body weight over 9 months improved insulin resistance and steatosis, and those subjects who lost >or=9% also achieved improved hepatic histologic changes...
  7. doi request reprint Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
    S A Harrison
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, San Antonio, USA
    Gut 57:1441-7. 2008
    ..Clinical predictors of advanced non-alcoholic liver disease (NAFLD) are needed to guide diagnostic evaluation and treatment...
  8. ncbi request reprint Current treatments in nonalcoholic steatohepatitis
    Dawn M Torres
    Stephen A Harrison, MD Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Curr Treat Options Gastroenterol 10:425-34. 2007
    ..Although most of these approaches have been studied as single-modality therapy, we believe that combination, multimodality therapy is required to treat this disease effectively...
  9. ncbi request reprint Impact of obesity on treatment of chronic hepatitis C
    Michael R Charlton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 43:1177-86. 2006
    ....
  10. doi request reprint Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study
    Daniel E Brady
    Department of Medicine, Brooke Army Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 8:66-71.e1. 2010
    ..Induction therapy with higher doses of PEG interferon may improve first-phase viral kinetics and thus improve the overall SVR in genotypes 1 and 4 patients...
  11. doi request reprint Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH)
    M Hjelkrem
    Brooke Army Medical Center, Gastroenterology Service, Fort Sam Houston, TX, USA
    Aliment Pharmacol Ther 35:1416-23. 2012
    ..We believe that unconjugated hyperbilirubinemia may protect against development of non-alcoholic steatohepatitis (NASH)...
  12. doi request reprint Diagnosis and therapy of nonalcoholic steatohepatitis
    Dawn M Torres
    Department of Gastroenterology, Fort Sam Houston, Brooke Army Medical Center, San Antonio, Texas 78234, USA
    Gastroenterology 134:1682-98. 2008
    ..Other potential therapeutic agents directed at cytoprotection or reduction of fibrosis are under investigation. This article focuses on diagnosis and therapy available and under development for this chronic liver disease...
  13. ncbi request reprint Effect of weight loss on nonalcoholic fatty liver disease
    Anish A Patel
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    J Clin Gastroenterol 43:970-4. 2009
    ..This review discusses dietary modification, exercise, weight loss pharmacotherapy, and surgical intervention as potential options for patients with NAFLD...
  14. ncbi request reprint A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Renata Belfort
    University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    N Engl J Med 355:2297-307. 2006
    ..Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus...
  15. ncbi request reprint A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients
    S A Harrison
    Department of Gastroenterology, Brooke Army Medical Center, San Antonio, TX 78234, USA
    Aliment Pharmacol Ther 20:623-8. 2004
    ..Treatment options for non-alcoholic steatohepatitis (NASH) are limited. Weight loss remains the most recommended therapy. Orlistat is an effective adjunct to dietary weight loss therapy...
  16. ncbi request reprint Liver disease in patients with diabetes mellitus
    Stephen A Harrison
    Department of Hepatology, Brooke Army Medical Center, Fort Sam, Houston, TX, USA
    J Clin Gastroenterol 40:68-76. 2006
    ..The association with diabetes and cirrhosis, acute liver failure, hepatocellular carcinoma, and outcomes following orthotopic liver transplantation will also be discussed...
  17. ncbi request reprint Extrahepatic manifestations of hepatitis C
    Nicole A Palekar
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, Fort Sam Houston, TX, USA
    South Med J 98:1019-23. 2005
    ..This paper serves to review the growing body of literature detailing the extrahepatic manifestations of chronic hepatitis C...
  18. ncbi request reprint Steatosis and chronic hepatitis C infection: mechanisms and significance
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Clin Gastroenterol Hepatol 3:S92-6. 2005
    ....
  19. ncbi request reprint Orlistat in the treatment of NASH: a case series
    Stephen A Harrison
    Saint Louis University Liver Center, Division of Gastroenterology and Hepatology, St Louis, Missouri 63110, USA
    Am J Gastroenterol 98:926-30. 2003
    ....
  20. doi request reprint Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis
    Amalia Gastaldelli
    Diabetes Division, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Hepatology 50:1087-93. 2009
    ..02 versus placebo). Adipo-IR decreased by 47% and correlated with the reduction of hepatic fat (r=0.46, P=0.009) and with the reduction in hepatic necroinflammation (r=0.47, P=0.0007)...
  21. ncbi request reprint Inflammatory bowel disease: thinking outside of the intestines (Part 2)
    Jonathan M Ricker
    Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
    J Miss State Med Assoc 49:365-9. 2008
    ..This article will review the EMs of IBD which involve the hematologic, cardiovascular, pulmonary, neurologic and urinary systems...
  22. ncbi request reprint Pharmacologic management of nonalcoholic fatty liver disease
    Stephen A Harrison
    Brooke Army Medical Center, Department of Gastroenterology and Hepatology, 3851 Roger Brooke Drive, Ft Sam Houston, TX 78234, USA
    Clin Liver Dis 8:715-28, xii. 2004
    ..This article focuses on the various therapeutic agents that have been evaluated in the treatment of NAFLD and their efficacy as well as their limitations...
  23. ncbi request reprint Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Stephen A Harrison
    Department of Gastroenterology and Hepatology, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Clin Liver Dis 8:861-79, ix. 2004
    ..The article includes current thoughts on the natural history and pathogenesis of NAFLD and describes current trends in the diagnosis and treatment of this condition...
  24. ncbi request reprint Inflammatory bowel disease: thinking outside of the intestines (Part 1)
    Jonathan M Ricker
    Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
    J Miss State Med Assoc 49:359-64. 2008
    ..This article will review the EMs of IBD which involve the hepatobiliary, mucocutaneous, musculoskeletal and ophthalmologic systems...
  25. ncbi request reprint Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C
    Stephen A Harrison
    Saint Louis University Liver Center, Saint Louis University, St Louis, MS, USA
    Clin Gastroenterol Hepatol 3:604-9. 2005
    ..The aim of this study was to evaluate SVR in patients with CHC plus steatosis or SH on biopsy examination, compared with a group of controls with CHC and no significant steatosis or SH...
  26. ncbi request reprint Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
    Stephen A Harrison
    Brooke Army Medical Center, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA
    Am J Gastroenterol 98:2485-90. 2003
    ..There is currently no proven medical therapy for the treatment of NASH. The aim of our study was to evaluate the efficacy of combination alpha-tocopherol (vitamin E) and vitamin C in reducing histologic inflammation and fibrosis...
  27. ncbi request reprint Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?
    F K F Cheng
    Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC, USA
    J Viral Hepat 21:1-8. 2014
    ..The pathways for both lipid homeostasis and NAFLD as it pertains to CHC infection as well as the utilization of statin therapy in CHC infection will be reviewed with a focus on the relevance of these topics in the era of DAA therapy. ..
  28. doi request reprint Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime
    J J Blonsky
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Aliment Pharmacol Ther 27:855-65. 2008
    ..Both nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC) are frequent causes of chronic liver disease. In recent years, there have been significant revelations as regards the relationship between NAFLD and CHC...
  29. ncbi request reprint NASH and HCC
    John M Page
    Department of Medicine, Gastroenterology Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234, USA
    Clin Liver Dis 13:631-47. 2009
    ..It is increasingly recognized that non-alcoholic steatohepatitis likely accounts for a substantial portion of cryptogenic hepatocellular carcinoma...
  30. ncbi request reprint The natural history of nonalcoholic fatty liver disease: a clinical histopathological study
    Stephen A Harrison
    Department of Gastroenterology, Wilford Hall Medical Center, Brooke Army Medical Center, San Antonio, Texas, USA
    Am J Gastroenterol 98:2042-7. 2003
    ..We aimed to define nonalcoholic steatohepatitis (NASH) histopathological change over time and to correlate changes with clinical characteristics...
  31. doi request reprint Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection
    Brad Q Starley
    Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 51:1820-32. 2010
    ..The complications of NASH, including cirrhosis and HCC, are expected to increase with the growing epidemic of diabetes and obesity...
  32. ncbi request reprint Advances in the understanding and treatment of nonalcoholic fatty liver disease
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, Missouri, USA
    Drugs 63:2379-94. 2003
    ....
  33. ncbi request reprint Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
    Bogdan Balas
    Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Room 3 380S, 7703 Floyd Curl Drive, San Antonio, TX 78284 3900, USA
    J Hepatol 47:565-70. 2007
    ..To understand the nature of weight gain associated with pioglitazone treatment in NASH we analyzed 35 patients who completed tests for determination of whole body fat (WBF) and total body water (TBW)...
  34. doi request reprint Validation of the non-alcoholic fatty liver disease activity score
    M Hjelkrem
    Division of Gastroenterology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Aliment Pharmacol Ther 34:214-8. 2011
    ..However, the NAS and the correlation between the NAS and a diagnosis of NASH have not been validated outside the NASH CRN...
  35. ncbi request reprint Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery
    Kevin B Barker
    Wilford Hall Medical Center, San Antonio, Texas, USA
    Am J Gastroenterol 101:368-73. 2006
    ..Treatment options are still under investigation. The primary aim of the study was to determine whether weight loss, achieved through Roux-en-Y gastric bypass (RYGBP), improved histopathology in obese patients with biopsy proven NASH...
  36. ncbi request reprint Nonalcoholic steatohepatitis: what we know in the new millennium
    Stephen A Harrison
    Department of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Am J Gastroenterol 97:2714-24. 2002
    ..Current investigations are focusing on improving the underlying insulin resistance that has been associated with NASH as well as other therapies that decrease oxidative stress or improve hepatocyte survival...
  37. ncbi request reprint Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease
    Nicole A Palekar
    Wilford Hall Medical Center, San Antonio, TX 78258, USA
    Liver Int 26:151-6. 2006
    ..In conclusion, we propose a noninvasive screening model for distinguishing simple steatosis from NASH. Identifying patients at risk for NASH will allow clinicians to more accurately determine who may benefit from liver biopsy...
  38. ncbi request reprint Fat and the liver--a molecular overview
    Stephen A Harrison
    Brooke Army Medical Center, Ft Sam Houston TX, USA
    Semin Gastrointest Dis 13:3-16. 2002
    ..A better understanding of these mechanisms is desired to target treatments to prevent and/or reverse nonalcoholic steatohepatitis, thereby aborting the evolution of cirrhosis...
  39. ncbi request reprint Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease
    Shane J Mills
    Department of Medicine, Gastroenterology and Hepatology Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234 6200, USA
    Curr Gastroenterol Rep 7:32-6. 2005
    ..Although they are histologically indistinct, AFLD and NAFLD follow different clinical courses. This article compares the natural history of these diseases...
  40. doi request reprint HCV in patients with end-stage renal disease
    Emuejevoke J Okoh
    Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA
    Am J Gastroenterol 103:2123-34. 2008
    ..Finally, with regard to postrenal transplant treatment of HCV infection, there is no evidence to support treatment with interferon-based therapy and pretransplant treatment remains the best option whenever possible...
  41. ncbi request reprint New advances in evaluation and management of patients with polycystic liver disease
    Hays L Arnold
    Gastroenterology Service, Department of Medicine, Brooke Army Medical Center, Fort Sam, Houston, Texas 78234 6200, USA
    Am J Gastroenterol 100:2569-82. 2005
    ..The surgical literature on treatment of APLD, to include outcome measurements and complication rates are summarized. Additionally, we review other potential organ involvement and resultant complications...
  42. ncbi request reprint Small molecule and novel treatments for chronic hepatitis C virus infection
    Stephen A Harrison
    Brooke Army Medical Center, Division of Gastroenterology and Hepatology, Department of Medicine, Fort Sam Houston, Texas, USA
    Am J Gastroenterol 102:2332-8. 2007
    ..In conclusion, small molecule and novel therapies for HCV infection are showing promise in clinical trials, and research to develop new agents and optimize treatment regimens is ongoing...
  43. ncbi request reprint Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass
    Steven P Larson
    Division of Gastroenterology and Hepatology, Wilford Hall Medical Center, San Antonio, Texas, USA
    Clin Gastroenterol Hepatol 5:1329-32. 2007
    ..Our aim was to assess for significant regional differences in histopathology between the right and left lobes of the liver in morbidly obese patients undergoing bariatric surgery...
  44. ncbi request reprint Diabetic hepatosclerosis: diabetic microangiopathy of the liver
    Stephen A Harrison
    Liver Center, Department of Medicine, Saint Louis University School of Medicine, St Louis, MO 63110, USA
    Arch Pathol Lab Med 130:27-32. 2006
    ..After observing a noncirrhotic form of hepatic sinusoidal fibrosis in patients with long-standing diabetes mellitus who underwent liver biopsy, we set about to characterize this novel entity...
  45. doi request reprint Insulin resistance and hepatitis C: an evolving story
    Mohammed Eslam
    Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Gut 60:1139-51. 2011
    ....
  46. ncbi request reprint Hereditary hemochromatosis: update for 2003
    Stephen A Harrison
    Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, Mo 63110 0250, USA
    J Hepatol 38:S14-23. 2003
  47. ncbi request reprint Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related
    Paul H Hayashi
    Wilford Hall Medical Center, Gastroenterology and Pathology Departments, Brooke Army Medical Center, San Antonio, Texas, USA
    Am J Gastroenterol 99:76-81. 2004
    ..We aimed to determine the prevalence of significant alcohol intake in previously diagnosed nonalcoholic fatty liver (NAFL) patients...
  48. ncbi request reprint Same day endoscopy and percutaneous liver biopsy: safety and cost-effectiveness
    J Aaron Cook
    Brooke Army Medical Center, 3841 Roger Brooke Drive, Ft Sam Houston, TX 78234, USA
    Dig Dis Sci 54:1753-7. 2009
    ..001). In conclusion, endoscopy and percutaneous liver biopsy can safely be performed in the same patient on the same day, which simultaneously increases patient satisfaction and is cost-effective...
  49. ncbi request reprint Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase
    Matthew W Pantsari
    Brooke Army Medical Center, San Antonio, TX, USA
    J Clin Gastroenterol 40:633-5. 2006
    ..To define a subset of patients with nonalcoholic fatty liver disease (NAFLD) with isolated elevations in alkaline phophatase...
  50. ncbi request reprint The role of vitamin E and C therapy in NASH
    Stephen A Harrison
    Am J Gastroenterol 99:1862. 2004
  51. ncbi request reprint HCV replication and statin pleotropism: an adjuvant treatment panacea?
    Dawn M Torres
    Am J Gastroenterol 103:1390-2. 2008
    ..While limited by heterogeneous patient population and overall small numbers, this study provides hope that use of statins in combination with standard therapy pegylated interferon and ribavirin may improve SVR...
  52. ncbi request reprint HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome
    Stephen A Harrison
    J Hepatol 44:624-6. 2006
  53. ncbi request reprint Correlation between insulin resistance and hepatitis C viral load
    Stephen A Harrison
    Hepatology 43:1168; author reply 1168-9. 2006
  54. ncbi request reprint An AFLP-based survey of genetic diversity among accessions of sea oats (Uniola paniculata, Poaceae) from the southeastern Atlantic and Gulf coast states of the United States
    Prasanta K Subudhi
    Department of Agronomy and Environmental Management, Louisiana State University Agricultural Center, 104 M B Sturgis Hall, Baton Rouge, LA 70803, USA
    Theor Appl Genet 111:1632-41. 2005
    ....